Your session is about to expire
← Back to Search
Anticonvulsant Agent
Perampanel for Low Grade Glioma
Phase 4
Waitlist Available
Led By William Tatum
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up at 3 months
Awards & highlights
Study Summary
This trial studies the side effects of perampanel and how well it works in reducing seizure frequency in patients with high-grade glioma and focal epilepsy.
Eligible Conditions
- Low Grade Glioma
- Gliomas
- Epilepsy
- Malignant Glioma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ at 3 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~at 3 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Decline in Neuropsychological Function
Number of Participants Alive at 3 Months With High-grade Glioma Treated With PER
Number of Patients With a High-grade Glioma Who Achieve a > 50% Reduction in Focal Seizures With PER 4 mg Daily After Failing 1 or More ASDs
+1 moreSide effects data
From 2021 Phase 4 trial • 54 Patients • NCT0328812928%
Dizziness
17%
Fatigue
15%
Somnolence
11%
Vomiting
9%
Nasopharyngitis
9%
Irritability
9%
Headache
7%
Nausea
7%
Ear infection
6%
Upper respiratory tract infection
6%
Balance disorder
6%
Memory impairment
6%
Aggression
6%
Depression
6%
Oropharyngeal pain
2%
Mental status changes
2%
Sudden unexplained death in epilepsy
2%
Transient ischaemic attack
2%
Suicidal ideation
100%
80%
60%
40%
20%
0%
Study treatment Arm
Perampanel 12 mg
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: Arm A (perampanel)Experimental Treatment3 Interventions
Patients receive perampanel PO QD for 40 weeks in the absence of disease progression or unacceptable toxicity.
Group II: Arm B (ASD)Active Control3 Interventions
Patients receive ASD per standard of care for 40 weeks in the absence of disease progression or unacceptable toxicity.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Perampanel
2014
Completed Phase 4
~2890
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,242 Previous Clinical Trials
3,773,745 Total Patients Enrolled
National Cancer Institute (NCI)NIH
13,717 Previous Clinical Trials
40,953,359 Total Patients Enrolled
William TatumPrincipal InvestigatorMayo Clinic
1 Previous Clinical Trials
20 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger